211 related articles for article (PubMed ID: 34737698)
21. The Modulatory Properties of
Liu C; Wang K; Zhuang J; Gao C; Li H; Liu L; Feng F; Zhou C; Yao K; Deng L; Wang L; Li J; Sun C
Front Pharmacol; 2019; 10():1171. PubMed ID: 31680955
[No Abstract] [Full Text] [Related]
22. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
23. Integrated network pharmacology and experimental verification to explore the potential mechanism of San Ying decoction for treating triple-negative breast cancer.
Yang X; Li F; Shi Y; Wu Y; Yang R; Liu X; Zhang Y; Zhang G; Ma M; Luo Z; Han X; Xie Y; Liu S
Acta Biochim Biophys Sin (Shanghai); 2024 May; 56(5):763-775. PubMed ID: 38516703
[TBL] [Abstract][Full Text] [Related]
24. Identifying the Effect of Ursolic Acid Against Triple-Negative Breast Cancer: Coupling Network Pharmacology With Experiments Verification.
Zhang Y; Ma X; Li H; Zhuang J; Feng F; Liu L; Liu C; Sun C
Front Pharmacol; 2021; 12():685773. PubMed ID: 34858165
[TBL] [Abstract][Full Text] [Related]
25. Long noncoding RNA Linc00339 promotes triple-negative breast cancer progression through miR-377-3p/HOXC6 signaling pathway.
Wang X; Chen T; Zhang Y; Zhang N; Li C; Li Y; Liu Y; Zhang H; Zhao W; Chen B; Wang L; Yang Q
J Cell Physiol; 2019 Aug; 234(8):13303-13317. PubMed ID: 30618083
[TBL] [Abstract][Full Text] [Related]
26. Anti-breast cancer effects and mechanisms of Xihuang pill on human breast cancer cell lines.
Pan G; Wang W; Wang L; Zhang F; Yin X; Wang J; Liang R
J Tradit Chin Med; 2013 Dec; 33(6):770-8. PubMed ID: 24660610
[TBL] [Abstract][Full Text] [Related]
27. Xihuang pill promotes apoptosis of Treg cells in the tumor microenvironment in 4T1 mouse breast cancer by upregulating MEKK1/SEK1/JNK1/AP-1 pathway.
Su L; Jiang Y; Xu Y; Li X; Gao W; Xu C; Zeng C; Song J; Weng W; Liang W
Biomed Pharmacother; 2018 Jun; 102():1111-1119. PubMed ID: 29710529
[TBL] [Abstract][Full Text] [Related]
28. Coexpression Network Analysis of Genes Related to the Characteristics of Tumor Stemness in Triple-Negative Breast Cancer.
Suo HD; Tao Z; Zhang L; Jin ZN; Li XY; Ma W; Wang Z; Qiu Y; Jin F; Chen B; Cao Y
Biomed Res Int; 2020; 2020():7575862. PubMed ID: 32766313
[TBL] [Abstract][Full Text] [Related]
29. Exploring the molecular targets and mechanisms of [10]-Gingerol for treating triple-negative breast cancer using bioinformatics approaches, molecular docking, and
Huang P; Zhou P; Liang Y; Wu J; Wu G; Xu R; Dai Y; Guo Q; Lu H; Chen Q
Transl Cancer Res; 2021 Nov; 10(11):4680-4693. PubMed ID: 35116323
[TBL] [Abstract][Full Text] [Related]
30. Xihuang pill induces pyroptosis and inhibits progression of breast cancer cells via activating the cAMP/PKA signalling pathway.
Chen C; Yuan S; Chen X; Xie J; Wei Z
Am J Cancer Res; 2023; 13(4):1347-1362. PubMed ID: 37168335
[TBL] [Abstract][Full Text] [Related]
31. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
[TBL] [Abstract][Full Text] [Related]
32. [Experimental study on anti-tumor effect of xihuang pill and its immune clearance function].
Ma J; Wang YY; Yang W; Guan S; Zeng CQ; Gao WB; Liang WB
Zhongguo Zhong Yao Za Zhi; 2014 Apr; 39(8):1499-501. PubMed ID: 25039190
[TBL] [Abstract][Full Text] [Related]
33. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.
Drago-Ferrante R; Pentimalli F; Carlisi D; De Blasio A; Saliba C; Baldacchino S; Degaetano J; Debono J; Caruana-Dingli G; Grech G; Scerri C; Tesoriere G; Giordano A; Vento R; Di Fiore R
Oncotarget; 2017 Apr; 8(17):28939-28958. PubMed ID: 28423652
[TBL] [Abstract][Full Text] [Related]
34. Clinical Effects of Xihuang Pill Combined with Chemotherapy in Patients with Advanced Colorectal Cancer.
Yu D; An GY
Evid Based Complement Alternat Med; 2017; 2017():5936086. PubMed ID: 28458715
[No Abstract] [Full Text] [Related]
35. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
36. A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.
Lasham A; Mehta SY; Fitzgerald SJ; Woolley AG; Hearn JI; Hurley DG; Ruza I; Algie M; Shelling AN; Braithwaite AW; Print CG
Int J Cancer; 2016 Sep; 139(5):1157-70. PubMed ID: 27072400
[TBL] [Abstract][Full Text] [Related]
37. Network pharmacology analysis of the anti-cancer pharmacological mechanisms of Ganoderma lucidum extract with experimental support using Hepa1-6-bearing C57 BL/6 mice.
Zhao RL; He YM
J Ethnopharmacol; 2018 Jan; 210():287-295. PubMed ID: 28882624
[TBL] [Abstract][Full Text] [Related]
38. Long non-coding RNA CCAT2 promotes oncogenesis in triple-negative breast cancer by regulating stemness of cancer cells.
Xu Z; Liu C; Zhao Q; Lü J; Ding X; Luo A; He J; Wang G; Li Y; Cai Z; Wang Z; Liu J; Liu S; Li W; Yu Z
Pharmacol Res; 2020 Feb; 152():104628. PubMed ID: 31904506
[TBL] [Abstract][Full Text] [Related]
39. Network pharmacology-based evaluation of natural compounds with paclitaxel for the treatment of metastatic breast cancer.
Rathaur P; Soni MN; Gelat B; Rawal R; Pandya HA; Johar K
Toxicol Appl Pharmacol; 2021 Jul; 423():115576. PubMed ID: 34000264
[TBL] [Abstract][Full Text] [Related]
40. Sanyin Formula Enhances the Therapeutic Efficacy of Paclitaxel in Triple-Negative Breast Cancer Metastases through the JAK/STAT3 Pathway in Mice.
Wu C; Sun C; Han X; Ye Y; Qin Y; Liu S
Pharmaceuticals (Basel); 2022 Dec; 16(1):. PubMed ID: 36678509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
